Integrase inhibitors effective against human T-cell leukemia virus type 1

Muhammad E. Seegulam
Washington University School of Medicine in St. Louis
Lee Ratner
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Part of the Medicine and Health Sciences Commons

Please let us know how this document benefits you.

Recommended Citation
https://digitalcommons.wustl.edu/open_access_pubs/95

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Integrase inhibitors effective against human T-cell leukemia virus type 1

Muhammad E Seegulam, Lee Ratner*

From 15th International Conference on Human Retroviruses: HTLV and Related Viruses
Leuven and Gembloux, Belgium. 5-8 June 2011

Drugs targeting the viral enzyme integrase have been in use for several years as part of the treatment regimen for patients with Human Immunodeficiency Virus Type 1 (HIV-1) and similar classes of compounds have been shown to inhibit Human T-Cell Leukemia Virus Type 1 (HTLV-1) integration in vitro. The current study shows that the clinically approved HIV-1 integrase inhibitor, Raltegravir, as well as the more recent diketo acid derivative, MK-2048, are active inhibitors of HTLV-1 infection in vitro. These agents were effective in inhibiting cell-free and cell-to-cell transmission of HTLV-1 in lymphoid and non-lymphoid cells. The drugs also inhibited HTLV-1 immortalization of human peripheral blood mononuclear cells. A novel adaptation of the Alu assay for viral integration was used to show that the drugs inhibit viral integration without affecting reverse transcription. These data support the administration of Raltegravir and other integrase inhibitors as treatments for patients with HTLV-1 associated diseases.

Published: 6 June 2011

doi:10.1186/1742-4690-8-S1-A34
Cite this article as: Seegulam and Ratner: Integrase inhibitors effective against human T-cell leukemia virus type 1. Retrovirology 2011 8(Suppl 1):A34.